Editorial & Columns Sustainable Finance in India: Gaining Traction October 9, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Dividend Policy dynamics of Pharmaceutical Companies in India October 4, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Indian Pharmaceutical Companies: Investment in R&D for “Jai Anusandhan” September 25, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Forex Rate Risk: Measurement and Mitigation by Pharmaceutical Companies in India September 14, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Skin in the Game: Decrease in Promoter Holding of Pharmaceutical Companies in India September 4, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Board Characteristics of Pharmaceutical Companies in India August 28, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Reporting on Scope 3 Emissions: Learning from Global Pharmaceutical MNCs August 21, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Different Routes and Same Destination: Indian Pharmaceutical & FMCG Companies in Wellness Segment August 14, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Risk Management and Pharmaceutical Companies in India August 6, 2024 | Dr. Anil Kumar Angrish | No Comments | More